In comparison to PSA in meta-analysis, the adjunct of DRE is likely to improve specificity and with minimal or no benefit in sensitivity for clinically significant prostate cancer (csPCa) in contemporary settings [27]. This evidence concerns the gene KLK3 and prostate cancer.